Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China

Next Previous
Trial Profile

An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Amgen

Most Recent Events

  • 09 Jul 2021 According to a BeiGene media release, the China National Medical Products Administration (NMPA) has conditionally approved KYPROLIS (carfilzomib) for injection in combination with dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma who have received at least two prior therapies, based on data from this trial.
  • 15 Jun 2021 Status changed from active, no longer recruiting to completed.
  • 12 Sep 2019 According to an Amgen media release, data from this trial will be presented at the 17th International Myeloma Workshop (IMW) 2019 in Boston, Sept. 12-15, 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top